At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Randomized, Placebo-Controlled, Double-Blind, Crossover, Study of the Pharmacodynamic Effects of CST-103 Co-administered With CST-107 on the Central Nervous System in Subjects With Neurodegenerative Disorders
In Brief
A Phase 2 clinical trial evaluating clenbuterol (CST-103), nadolol (CST-107), matching placebo for Mild Cognitive Impairment, Lewy Body Dementia, Parkinson's Disease Rapid Eye Movement Sleep Behavior Disorder, Parkinson's Disease Dementia. Completed, enrolled 41 participants across 7 sites in 3 countries.
Detailed Summary
This is a Phase II, randomized, placebo-controlled, double-blind, crossover study on the CNS and pharmacodynamic effects of clenbuterol (CST-103) co-administered with nadolol (CST-107) in 4 subject populations with Neurodegenerative Disorders.
Study Details
Timeline
Interventions
clenbuterol (CST-103) and matching placebo orange capsules; nadolol (CST-107) and matching placebo white capsules